Action Items

Facebook offers untapped potential in clinical trial recruitment

Wednesday, March 1, 2017

It’s no secret that difficulty recruit­ing patients can significantly delay a clinical trial. Our patient recruit­ment team at Corbett Clinical Tri­als recently struggled with this while identifying qualified patients for a rare metastatic cancer study. In order to identify prospective study patients who met the strict study entry criteria, we deployed a social media advertis­ing campaign that demonstrated the power of asking people to lend a help­ing hand.

[Read More]

A new era of clinical trial patient identification

Wednesday, February 15, 2017

One of the most pervasive struggles for clinical trial researchers is identifying and enrolling qualified trial participants. Traditional meth­ods are not only costly, but they also too often fail to draw an adequate pool of qualified participants.

[Read More]

Identifying opportunities in emerging markets

Wednesday, February 1, 2017

A strong technological and scien­tific infrastructure, world-class medical facilities and government in­centives and support are just some of the advantages medical professionals should take into consideration when identifying new business locations globally. Innovation cannot thrive without these components.

[Read More]

Eliminating the swivel chair clinical investigator

Sunday, January 15, 2017

There is a heavy burden on investi­gators and research nurses when executing clinical trials and clinical care. In addition to the normal com­plexities of patient recruitment and care, investigative sites are stuck in the middle of multiple data entry systems. They move back and forth between electronic data capture (EDC) and electronic medical record (EMR) ap­plications to make sure information is recorded accurately and in the right place—a situation commonly known as “swivel chair interoperability.”

[Read More]

Saving studies with reader and assessor training

Sunday, January 1, 2017

Although many CROs offer out­standing research capabilities, not every assessor or overreader receives sufficient instruction to reduce variability and error. To avoid multimillion-dollar misfor­tunes, sponsors should prioritize assessor and overreader education to improve data quality.

[Read More]

Why is there such inefficiency in site selection?

Thursday, December 15, 2016

This question is often asked about an industry deeply root­ed in paper-based, spreadsheet tools for clinical trial conduct. Study teams have continued to rely on these older tools and relation­ships with principal investigators that have developed over time to select sites, building an institu­tional knowledge about specific sites based on previous studies.

[Read More]

Why we need to redefine the “team” in rare disease trials

Thursday, December 1, 2016

Achieving a sponsor’s goals, though of utmost importance, should only be one area of emphasis during a clinical trial. One must also consider the broader team of stakeholders—the patients, their caregivers and their physicians. This is never more true than in the study of rare diseases.

[Read More]

Engaging patients for a more successful clinical trial

Tuesday, November 15, 2016

Recruitment has always been a key element to a successful clinical trial, and in the past several years the concept of patient engagement—be­yond getting patients in the door—has grown. Historically for rare and orphan disease trials, engagement has helped recruit patients and make sure they are familiar with the treatments involved in the study, which makes them more willing to utilize the treat­ment once it has been approved.

[Read More]